BSG and pancreatic neoplasm: Indeed, our previous findings indicated that anti-CD147 HAb18IgG sensitized pancreatic cancer cells to chemo-radiotherapy and reduced CSC potential by inhibiting pSTAT3 signaling (Fan et al., 2019), and the CD147 antibody drug, namely, Licartin, was successfully used to prevent tumor recurrence after liver transplantation or radiofrequency ablation in advanced hepatocellular carcinoma patients (Xu et al., 2007a; Bian et al., 2014).